Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06075810 · ClinicalTrials.gov registry record · Phase 1
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
A Phase 1 study of Breast Cancer and Breast Neoplasm, sponsored by MBQ Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 4
- Study locations
NCT06075810: Recruiting Phase 1 study of Breast Cancer and Breast Neoplasm, sponsored by MBQ Pharma.
NCT06075810 is a Phase 1 study of Breast Cancer and Breast Neoplasm that is actively recruiting participants, run by MBQ Pharma. The registered enrollment target is 48 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06075810, a Phase 1 study of Breast Cancer and Breast Neoplasm, is actively recruiting participants, sponsored by MBQ Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 4
- Study locations
Study Summary
A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.
Primary Outcome
To find the maximum tolerated dose (MTD) of MBQ-167 as a single agent administered orally, BID continuously for 21 days in participants with Advanced Breast Cancer (ABC) by evaluating for the presence or absence of dose-limiting toxicity (DLT) related to MBQ-167 administered in cohorts of participants at escalating sequential cohort dose levels.
Conditions Studied
Interventions
- DRUG MBQ-167
Study Locations (4)
California
- Precision Next Gen Oncology & Research Center - Beverly Hills
Florida
- Florida Cancer Specialists / Sarah Cannon Research Institute / SCRI - Sarasota
Tennessee
- Sarah Cannon Research Institute/SCRI - Nashville
Other
- FDI Clinical Research - San Juan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-11-09 |
| Est. Completion | 2025-10-31 |
| Phase | Phase 1 |
What NCT06075810 shows while recruiting
NCT06075810 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which MBQ-167 is the first listed.
NCT06075810 reports a single indexed study location in California, Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06075810 about?
NCT06075810 is a clinical study titled "A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer". A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.
What is the current status of trial NCT06075810?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2023-11-09. Estimated completion is 2025-10-31.
What conditions does trial NCT06075810 study?
This clinical trial studies the following conditions: Breast Cancer, Breast Neoplasm, Breast Cancer Stage IV.
What interventions are being tested in trial NCT06075810?
The interventions under investigation include: MBQ-167 (DRUG).
Who is sponsoring clinical trial NCT06075810?
This trial is sponsored by MBQ Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06075810 being conducted?
This trial has 4 study locations across California, Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06075810's enrollment target sits among peer trials
48 821st of 1224 higher than 394 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI